康莱特注射液联合放疗用于非小细胞肺癌的系统评价

Kanglaite Injection Combined with Radiothreapy in the Treatment of Non-small Cell Lung Cancer:A Systemaic Review

目的:系统评价康莱特注射液联合放疗用于非小细胞肺癌(NSCLC)的疗效和安全性,以为临床提供循证参考。方法:计算机检索Pub Med、Cochrane图书馆、EMBase、中文科技期刊数据库、中国期刊全文数据库、万方数据库和中国生物医学文献数据库,收集康莱特注射液联合放疗用于NSCLC疗效和安全性的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取,并采用改良后的Jadad量表进行质量评价,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入9项RCT,合计561例患者。Meta分析结果显示,康莱特注射液联合放疗能显著提高有效率[OR=2.99,95%CI(2.07,4.31),P<0.001]、生存质量改善率[OR=3.74,95%CI(2.36,5.92),P<0.001]和降低放射性肺炎发生率[OR=0.23,95%CI(0.12,0.47),P<0.001]、放射性食管炎发生率[OR=0.10,95%CI(0.05,0.21),P<0.001],与单纯放疗比较差异均有统计学意义。结论:康莱特注射液联合放疗用于NSCLC的疗效和安全性均优于单纯放疗。

OBJECTIVE： To systematically review the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of the non-small cell lung cancer （NSCLC）, and provide evidence-based reference for clinical treatment. METH- ODS： Retrieved from PubMed, Cochrane Library, EMBase, VIP, CJFD, Wanfang database and CBM, randomized controlled tri- als （RCT） about the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC were collect- ed. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation with modified Jadad scale. RESULTS： Totally 9 RCTs were included, involving 561 patients. Results of Meta-analysis showed, Kanglaite injection com- bined with radiothreapy can significantly improve the effective rate [OR=2.99, 95%CI（2.07,4.31）,P〈0.001] and improvement rate of life quality [OR=3.74,95%CI（2.36,5.92）,P〈0.001], and reduce the incidence of radiation pneumonitis [OR=0.23,95%CI （0.12, 0.47）, P〈0.001] and radiation esophagitis [OR=0.10, 95% CI （0.05, 0.21）, P〈0.001] of NSCLC patients, the differences were statistically significant. CONCLUSIONS： Both the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC are superior to radiothreapy alone.